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ral vectors, and high levels of recombinant protein expres-
sion. Efficient transduction with adenoviral vectors can be
achieved with 15 to 30 minutes of exposure, which is
comparable to the cross-clamp time required for many vas-
cular surgical procedures. Also, the ability to infect non-
replicating cells is critical for gene transfer to endothelial
and smooth muscle cells in vivo. These features make ade-
noviral vectors particularly suitable for gene transfer to the
blood vessels.
Adenoviral gene transfer to blood vessels has been
used to determine the in vivo function of particular pro-
teins1 and to inhibit neointimal hyperplasia in experimen-
tal models of restenosis.2 Although adenoviral gene
transfer to the vasculature has focused on large conduit
arteries and experimental models of diseases that affect
such vessels, prior studies from our laboratory have
focused on gene transfer to the limb capillary bed and
skeletal muscle fibers. We have shown that intra-arterial
administration of adenoviral vector into a rat hindlimb
under vascular isolation for 30 minutes results in biologi-
cally active levels of recombinant protein, which could be
detected both locally and systemically.3 The use of aden-
oviral vectors in the capillary bed of ischemic limbs could
potentially provide high-level expression of proteins tar-
Currently, adenoviral vectors are the most commonly
used vectors for direct in vivo gene transfer to a variety of
tissues and experimental models of disease. The advan-
tages of recombinant adenoviral vectors include the ability
to infect a wide variety of nonreplicating cells within brief
exposure periods, the potential for delivery of large
recombinant proteins that cannot be packaged in retrovi-
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Administration of adenoviral vectors induces
gangrene in acutely ischemic rat hindlimbs: Role
of capsid protein-induced inflammation
Lucy S. Brevetti, MD, Rajabrata Sarkar, MD, PhD, David S. Chang, MD, Madison Ma, BS, Robert
Paek, MD, and Louis M. Messina, MD, San Francisco, Calif
Purpose: The initial purpose of this study was to determine the effects of intravascular adenoviral vector-mediated gene
transfer of endothelial nitric oxide synthase (AdeNOS) on experimental hindlimb ischemia in the rat. Unexpectedly,
administration of AdeNOS immediately after induction of acute limb ischemia led to limb gangrene. We subsequently
sought to define the molecular mechanisms responsible for this unusual effect and to devise adenoviral gene transfer
strategies to prevent the development of gangrene in acutely ischemic limbs.
Methods: Phosphate-buffered saline or adenoviral vectors containing the bovine endothelial nitric oxide synthase gene
(AdeNOS) or no transgene (Ad-E1) were injected intra-arterially into the hindlimb of a rat under vascular isolation
immediately after surgical induction of severe ischemia. Hematoxylin and eosin staining was performed on muscle sec-
tions to evaluate inflammation. A separate group of animals was injected with an adenovirus containing a nontran-
scribable genome, treated with cyclosporine, or received delayed administration of the adenoviral vector. Gene
expression after delayed adenoviral gene transfer was assessed with immunohistochemistry, Western blotting, and nitric
oxide synthase (NOS) activity assay.
Results: Both AdeNOS and Ad-E1 caused gangrene of the entire hindlimb within 12 days in a dose-dependent man-
ner, at a threshold concentration of 1 × 109 plaque-forming unit/mL. Adenoviral delivery was associated with more
inflammation and edema compared with phosphate-buffered saline histologically. Inactivation of adenoviral DNA tran-
scription did not affect induction of gangrene. However, gangrene was prevented by concurrent immunosuppression
with cyclosporine or delayed administration of the vector. Delayed administration allowed adenoviral gene expression
as determined by immunohistochemistry, NOS protein levels, and an assay of NOS enzyme activity.
Conclusion: Intra-arterial administration of adenoviral vectors, under vascular isolation, immediately after induction of
acute ischemia causes inflammation and subsequent limb gangrene. The inflammatory response is unrelated to the
expression of the recombinant transgene or the adenoviral genome and is likely due to the adenoviral capsid proteins.
However, administration of cyclosporine or delayed injection of the adenoviral vector is a method that can be used for
adenoviral mediated gene transfer in limb ischemia. (J Vasc Surg 2001;34:489-96.)
geted to treatment of various aspects of limb ischemia.
Directed expression of recombinant angiogenic proteins
in the capillary bed could treat ischemia4 and could also be
used to express proteins that prevent small vessel throm-
bosis or promote tissue regeneration.
A detrimental feature in the use of adenoviral vectors
in vivo, particularly in vascular applications, has been a
local inflammatory reaction induced by the virus.
Although initial reports in which recombinant adenoviral
vectors were used to transduce the arterial wall did not
identify a significant inflammatory reaction,5,6 subsequent
studies in other models have shown significant vessel wall
inflammation after the administration of recombinant ade-
novirus to large vessels in vivo.1,7,8
Whereas our earlier studies demonstrate significant
gene expression in nonischemic hindlimbs,3 the effects of
adenoviral gene transfer to the capillary bed of an ischemic
limb remain unknown. Our preliminary studies demon-
strated that the intra-arterial administration of adenoviral
vectors in the setting of severe acute limb ischemia sur-
prisingly resulted in frank gangrene of the entire limb. The
purpose of this study was to characterize the mechanisms
responsible for this clinically significant phenomenon and
to devise experimental strategies that would allow aden-
oviral gene transfer in ischemic limbs.
MATERIALS AND METHODS
Adenoviral vectors. All adenoviral vectors contained
deletions of E1 and E3 regions and were replication defec-
tive. Adenoviral vector-mediated gene transfer of endothe-
lial nitric oxide synthase (AdeNOS) contains the bovine
endothelial nitric oxide synthase (eNOS) complementary
DNA driven by the Rous sarcoma virus promoter and was
a generous gift of Dr Beverly L. Davidson (University of
Iowa College of Medicine).9 Ad-E1, which is an identical
vector in all respects to AdeNOS yet does not contain a
transgene, was used as a control. Propagation of vectors
was performed as described.3 After two rounds of viral
purification with cesium chloride, viral stocks were dia-
lyzed twice against 3% sucrose and stored in 3% sucrose at
–80°C. Lack of replication competent virions was con-
firmed by a cytopathic effect (CPE) assay on HeLa cells.
In brief, HeLa cells at 106 per well in a six-well plate were
inoculated with the adenoviral vector at a multiplicity of
infection of 20 to 40 in 1 mL of media for 2 hours in
humidified 5% carbon dioxide atmosphere at 37°C. The
media were replaced and the cells incubated and moni-
tored daily for CPE. The cells were split 1:4 every 3 days
for 2 weeks without any signs of CPE. For animal experi-
ments, frozen vector stocks were thawed immediately
before use and were diluted in sterile phosphate-buffered
saline (PBS) to achieve a final concentrations ranging from
1 × 108 to 1 × 1010 plaque-forming unit (pfu)/mL. The
concentrations of all adenoviral vectors were assayed with
the optical absorbance assay and the standard plaque
assay.10 The optical absorbance is a physical assay per-
formed to measure the concentration of the adenoviral
particles. Briefly, a sample of the solution with the virions
is placed in a cuvette, and the optical density at 260 nm
(OD260) is measured. The concentration of virions is cal-
culated according to the data of Maizel et al.11 The plaque
assay is performed to measure the concentration of biolog-
ically infectious virions. In brief, 293 cells plated at 106 per
well in a six-well plate were incubated for 16 to 24 hours
in humidified 5% carbon dioxide atmosphere at 37°C. The
cells were inoculated with the adenoviral vector at serial
dilutions for 90 minutes. The vector-containing medium
was gently aspirated and discarded. The cells were overlaid
with minimal essential medium containing 15% fetal
bovine serum, 4 mmol/L glutamine, penicillin (100
U/mL), streptomycin (100 µg/mL), and 1% SeaPlaque
low-melting point agarose. Titer plates were then cultured
in a humidified, 5% carbon dioxide atmosphere at 37°C.
Plaques were counted on day 14 by visual inspection. The
mean of the number of plaques from three separate wells,
each inoculated with 100 µL of stock vector from dilution,
was determined, and the titer was calculated by multiply-
ing this value by the dilution factor. In our laboratory, the
ratio of total viral particles to biologically infectious virions
is ranges from 200 to 400:1.
8-Methoxypsoralen inactivation of adenovirus. To
determine if the deleterious effects of adenovirus adminis-
tration were due to the expression of adenoviral proteins
from open reading flames present within the vectors, we
used 8-methoxypsoralen (8-MOP)–inactivated adenoviral
vectors. The 8-MOP is an intercalating agent, which irre-
versibly prevents DNA transcription. Ultraviolet radiation
of 8-MOP–treated adenovirus causes cross-linking of the
adenoviral DNA strands, thus preventing its transcrip-
tion.12,13 A total of 300 µL per well of Ad-E1 was added to
wells of a 24-well tissue culture plate. The 8-MOP (Sigma,
Cat No M3501, St Louis, Mo) dissolved in dimethoxysul-
foxide was added to each well at a final concentration of
330 µg/mL. The plate was kept on ice and exposed to
ultraviolet light (365 nm at a distance of 3 cm) for 30 min-
utes. Unreacted 8-MOP was removed by means of dialysis
against 3% sucrose. The 8-MOP–treated Ad-E1 (8-
MOP/E1) was then assayed with two methods: a physical
assay, measuring the optical absorbance, and a biological
assay, with the standard plaque assay technique as above.
The physical assay is performed to measure the concentra-
tion of the adenoviral particles, and the biological assay is
performed to confirm inactivation of the viral genome.
Animals. A total of 35 male Sprague-Dawley rats
(300-350 gm; Simonsen, Gilroy, Calif) were used. Animals
were housed in an environmentally controlled room and
were given food and water ad libitum. The care of animals
complied with the Guide for the Care and Use of Laboratory
Animals (Institute of Laboratory Animal Resources,
Commission on Life Sciences, National research Council,
Washington, DC, National Academy Press, 1996). All pro-
tocols were approved in accordance with the Committee on
Animal Research at the University of California, San
Francisco.
Rat hindlimb ischemia model. Rats were anes-
thetized through the inhalation of 1% to 2% isofiurane. All
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surgery was performed with a stereomicroscope (Leica)
with a magnification of 16 to 25×. Hindlimb ischemia was
created by ligation of the left common iliac, external iliac,
and femoral arteries. The untreated right hindlimb arter-
ies served as an internal control. This model of ischemia
reduces the maximal blood flow in the ischemic gastroc-
nemius muscle by 36% at 24 days compared with unoper-
ated controls as measured with fluorescent microspheres
(data not shown). In this model, no rats had gangrene of
the ischemic hindlimb by 40 days. Adenoviral vectors were
infused either immediately after the induction of hindlimb
ischemia or 10 days after arterial ligation. All animals were
weighed and evaluated daily with examination of the
hindlimb and paws. Pressure sores, capillary refill, muscle
atrophy, clubbing of the toes, and gangrene were
recorded. Pressure sores were defined as partial-thickness
skin loss on the pads of the paws, which presents clinically
as a shallow ulcer. Capillary refill, the length of time
required for the paw to return to its normal pink color
after 1 to 2 seconds of blanching, was defined as normal
or delayed when compared with the contralateral (unop-
erated) side. Muscle atrophy was defined as a decrease in
muscle mass as a percent of total body mass. Gangrene was
defined as local soft tissue death involving the foot or
hindlimb.
Hindlimb vascular isolation and adenovirus infu-
sion. Hindlimb vascular isolation and intra-arterial
administration of adenoviral vectors in ischemic hindlimbs
were performed as we have described previously for non-
ischemic rat hindlimbs.3 Rats were anesthetized with
inhalation of 1% to 2% isoflurane, and a tourniquet was
applied at the level of the groin, excluding the femoral
nerve. The left femoral vein and its branches were
occluded with atraumatic microvascular clamps. The left
saphenous artery was isolated and cannulated with a blunt
26-gauge needle in retrograde fashion. A venotomy was
made in the saphenous vein, and the limb was infused
through the saphenous artery cannula with 10 mL of PBS
containing 50 U/mL heparin followed by 5 mL of PBS
without heparin. The venotomy was temporarily clamped,
and 0.7 mL of PBS or adenovirus (at concentrations rang-
ing from 1 × 108 to 1 × 1010 pfu/mL) was injected
through the saphenous artery. After a 30-minute incuba-
tion period, the vein clamp was removed, and vector was
flushed out of the limb by infusion of 5 mL of PBS. Both
the saphenous artery and vein were ligated with 5-0 silk
suture, and the clamps were removed. In selected animals,
8 mg/kg of cyclosporine was administered by intraperi-
toneal injection immediately after ischemia and vascular
isolation and continued daily for 7 days. This dose has pre-
viously been shown to prolong adenoviral gene expression
in vivo.14 In our laboratory, zero out of five rats developed
gangrene after induction of hindlimb ischemia and iso-
lated vascular perfusion with PBS and ligation of the
saphenous artery and vein.
An eNOS protein analysis with Western immuno-
blotting. Gastrocnemius muscles from left (ischemic) and
right (control) hindlimbs were harvested, weighed, and
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homogenized in ice-cold buffer (10 mmol/L Tris-HCl
pH 7.4, 1 mmol/L EDTA, 1 mmol/L EGTA, 0.25 mol/
L sucrose, and 20 µg/mL each phenylmethylsulfonyl flu-
oride, soybean trypsin inhibitor, leupeptin, and aprotinin)
and centrifuged at 3500 rpm for 30 minutes at 4°C.
Supernatant protein levels were determined by standard
BCA assay, and 90 µg of each sample was fractionated on
7.5% SDS-PAGE gels and transferred to nylon membranes
(Bio-Rad Laboratories, Hercules, Calif). After they were
blocked for 1 hour at room temperature with 5% nonfat
dry milk and 0.1% Tween 20, membranes were incubated
overnight with primary polyclonal rabbit anti-eNOS
(1:1000 in milk block) at 4°C (Transduction Laboratories,
Lexington, Ky). The membranes were washed in PBS with
0.05% Tween 20 for 30 minutes. The eNOS protein was
detected with horseradish peroxidase labeled with donkey
and antirabbit immunoglobulin G (IgG) secondary anti-
body (1:5000 in milk block) (Amersham, Life Science,
Inc, Piscataway, NJ) and visualized by chemiluminescence
with ECL Plus (Amersham, Life Science Inc).
Determination of nitric oxide synthase activity.
Nitric oxide synthase (NOS) activity was determined with
a commercial NOS assay (Calbiochem-Novabiochem
Corp, San Diego, Calif) that measures the conversion of
L-arginine to L-citrulline by NOS. Gastrocnemius muscles
were harvested, weighed, and homogenized in ice-cold
buffer (25 mmol/L Tris-HCl, pH 7.4, 1 mmol/L EDTA,
1 mmol/L EGTA) and centrifuged at 1500 rpm for 5
minutes at 4°C. Ten microliters of the supernatant was
added to 40 µL of reaction medium including reaction
buffer (50 mmol/L Tris-HCl, pH 7.4, 6 µmol/L tetrahy-
drobiopterin, 2 µmol/L FAD, 2 µmol/L FMN), 5 µL of
10 mmol/L NADPH, 1 µL of arginine labeled with car-
bon 14 (1 µCi/µL), 5 µL of 6 mmol/L CaCl2, and 4 µL
of H2O. Identical samples were prepared without CaCl2
to determine the amount of calcium-dependent NOS
activity. After an incubation of 30 minutes at 37°C, the
reaction was stopped with 400 µL of 50 mmol/L HEPES,
pH 5.5, and 5 mmol/L EDTA. We added 100 µL of equi-
librated anion exchange resin (Dowex-50) to the reaction
sample and centrifuged for 30 seconds at 1500 rpm. 14C-
labeled citrulline was quantitated in the supernatant with
a scintillation counter. The calcium-dependent NOS activ-
ity was calculated by subtracting the NOS activity mea-
sured without calcium from the total NOS activity
measured with calcium. The results are reported as the
amount of labeled citrulline (counts per minute) per mil-
ligram of protein in the homogenate.
Tissue preparation and histology. Hamstrings and
gastrocnemius muscles were harvested and weighed, and
the midsection was cut transversely, embedded in Gum
Tragacanth (Sigma) and frozen in precooled (at –70°C) 2-
methybutane (Fisher, Pittsburgh, Pa). Serial 10-µm thick
frozen sections of the muscles were adhered to poly-L-
lysine coated slides, air dried, and fixed in acetone and 1%
paraformaldehyde at 4°C for 5 minutes. Muscle sections
were stained with hematoxylin and eosin (H&E) 18 hours
after vascular isolation or with eNOS 3 days after delayed
isolation. Immunohistochemical analysis for eNOS was
performed with a mouse IgG monoclonal antibody to rat
eNOS (Transduction Laboratories). Goat serum (5%) and
0.2% bovine serum albumin were used for blocking non-
specific binding of protein for 20 minutes. Anti-eNOS
antibody (1:250) was incubated at 4°C overnight.
Sections were washed in PBS for 5 minutes, and biotinyl-
ated goat antimouse IgG was applied for 30 minutes.
Sections were again washed in PBS, and an avidin-biotin
horseradish peroxidase complex was applied for 30 min-
utes. Slides were rinsed with PBS, and 0.05% 3,3´-
diaminobenzidine tetrahydrochloride and 0.01%
hydrogen peroxide were applied for 5 minutes and washed
with water. Muscle sections were examined for inflamma-
tory cellular infiltrate and edema on H&E and positive
staining of eNOS (reddish-brown color) with light
microscopy and photographed (40× and 80×).
RESULTS
The effect of adenovirus on acute hindlimb
ischemia. Intra-arterial administration of adenoviral vec-
tors at 1 × 109 and 1 × 10l0 pfu/mL (AdeNOS and Ad-
E1) resulted in gangrene of the entire hindlimb (Fig 1, C,
and D). Within the first 24 to 48 hours all ischemic
hindlimbs were slightly cyanotic, dusky, and edematous.
The histologic appearance of the muscles after adenoviral
administration revealed more inflammatory cellular infil-
tration and edema than PBS (Fig 2). After 3 days, the con-
trol animals (injected with PBS, n = 5) improved in color,
and their edema began to resolve. By the seventh postop-
erative day, pressure sores developed on the pads of the
paws. Hindlimbs that were treated with adenoviral vectors
became a darker purple after 3 or 4 days. By the 12th day,
gangrene (demarcated level of nonviable tissue) devel-
oped, and the animals were humanely killed. The admin-
istration of adenovirus at a lower titer (1 × 108 pfu/mL)
did not appear to cause limb gangrene, and we subse-
quently performed a complete dose-response experiment
to determine if the incidence of gangrene was related to
viral titer. The administration of increasing titers of either
AdeNOS or Ad-E1 resulted in an increasing incidence of
limb gangrene (Fig 3) with no gangrene seen at 1 × 108
pfu/mL, and all animals had gangrene at 1 × 1010
pfu/mL. The occurrence of limb gangrene was sporadic at
intermediate titers with some animals having complete
necrosis of the hindlimb (Fig 1, D) and others, which
received the same titer, showing no tissue loss.
The role of adenoviral gene expression in the cause
of gangrene. Treating the adenoviral vector with 8-MOP
and exposing it to ultraviolet light prevented adenoviral
gene expression. This method prevents DNA transcription
in the viral particles, including any transgene. The original
particle concentration of the stock adenovirus (Ad-E1)
was 6 × 1012 part/mL. After treatment, the total particle
concentration of the AdMOP/E1 was 3.1 × 1012
part/mL. The plaque assay demonstrated that 8-MOP
treatment destroyed the ability of the adenovirus to infect
293 cells, in which the growth of replication-incompetent
E1-deleted adenoviral strains is permissive.15 No plaques
were visualized after 2 weeks with an 8-log dilution.
However, the stock adenovirus (Ad-E1) had 30 plaques
with a 9-log dilution and 3 plaques with a 10-log dilution
(3 × 1010 pfu/mL). The resulting titer of the 8-
MOP–treated adenovirus (< 108 pfu/mL) is less than a
dose of adenovirus (1 × 108 pfu/mL) not treated with 8-
MOP that did not cause gangrene (Figs l, B, and 3).
The animals that were treated with AdMOP/E 1 were
given an equivalent particle concentration as those that
received Ad-E1 or AdeNOS (2 × 1012 part/mL). All three
animals that received the AdMOP/E1 also had gangrene
by 7 days postoperatively (Fig 4, D), demonstrating that it
is the adenoviral particle and not gene expression from the
adenoviral genome that is responsible for limb gangrene.
Effect of immunosuppression on adenovirus-
induced gangrene. Cyclosporine has been shown to pre-
vent immune-mediated reduction in adenoviral gene
expression and to decrease the inflammatory response
induced by adenovirus.16 Immediately after ischemia and
vascular isolation with intra-arterial injection of Ad-E1 at
1 × 109 pfu/mL (a dose that consistently produced limb
gangrene), rats were treated with cyclosporine for 7 days.
All three animals that underwent treatment with
cyclosporine that began immediately after gene adminis-
tration and daily thereafter for 7 days had no signs of gan-
grene by the seventh postoperative day (Fig 4, C). There
was no evidence of toxicity from the cyclosporine, such as
seizures.
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Fig 1. Appearance of ischemic hindlimb after intra-arterial
adenoviral gene transfer as a function of viral titer (3-11 days after
delivery). A, PBS. Note absence of gangrene. B, Ad-E1 at 1 ×
108 pfu/mL. Note gangrenous toes (occurred in 1 of 3 animals).
C, Ad-E1 at 1 × 109 pfu/mL. D, Ad-E1 at 1 × 1010 pfu/mL.
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Fig 2. The H&E staining of hamstring muscle harvested 1 day after intra-arterial delivery of PBS (A) and AdeNOS
(B) and in an acutely ischemic hindlimbs (C). Note presence of edema and vasculitis (black arrow) in adenoviral-treated
muscle 40× (B). Inflammatory cellular infiltration (open arrow) was also greater in adenoviral-treated groups 80× (C).
Fig 3. Relationship between PBS or adenoviral titer and incidence of gangrene after intra-arterial administration of ade-
novirus. Percent of ischemic hindlimbs that developed gangrene after intra-arterial delivery of adenoviral vector at their
respective titers (1E + 8 = 1 × 108 pfu/mL).
Delayed administration of adenovirus in limb
ischemia. We hypothesized that delaying the administra-
tion of adenoviral vector until the acute inflammatory
response to induction of ischemia had subsided would
prevent the development of gangrene. Ten days after
ischemia was induced, the adenoviral vector was adminis-
tered as described above. No gangrene was noted after 14
days in the three animals that received delayed administra-
tion of Ad-E1 at 1 × 1010 pfu/mL or in the three rats that
received delayed administration of PBS (Fig 4, A and B).
This same dose of adenovirus (1 × 1010 pfu/mL) consis-
tently produced gangrene when administered at the same
time that ischemia was induced (Fig 3).
We then proceeded to evaluate adenoviral gene
expression after delayed administration in ischemic
hindlimbs. Western blot analysis demonstrated easily
detectable gene expression of eNOS protein 3 days and 5
days after delayed administration of AdeNOS at 1 × 1010
pfu/mL (Fig 5), which was not seen in the contralateral
(right) limb or in the animals receiving Ad-E 1 adenovirus.
NOS activity assay performed on the gastrocnemius mus-
cle of rats 3 days after either AdeNOS or Ad-E1 adeno-
virus demonstrated a 10-fold increase in NOS activity in
the animals receiving AdeNOS virus (444106 ± 39730
cpm/mg vs 174939 ± 49707 cpm/mg protein, calcium-
dependent activity, AdeNOS vs Ad-E1, n = 3, Student t
test, P < 05). Immunohistochemical staining of the gas-
trocnemius muscle 3 days after administration of AdeNOS
revealed strong staining for eNOS protein in comparison
with the muscle treated with Ad-E1 (Fig 6).
DISCUSSION
We studied the ability of adenoviral vectors to achieve
gene transfer into capillary beds of ischemic limbs and
examined the effect of adenovirus infusion on limb
ischemia. Our major findings were that (1) arterial admin-
istration of adenoviral vectors caused gangrene of an
ischemic rat hindlimb in a dose-dependent manner, (2)
prevention of adenoviral DNA transcription by psoralen
failed to prevent the development of gangrene, (3)
immunosuppression with cyclosporine prevented the
development of gangrene, and (4) delayed administration
of AdeNOS by 10 days after the development of ischemia
prevented the development of gangrene and achieved ele-
vated expression of eNOS.
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Fig 5. Western blot of gastrocnemius muscle harvested 3 and 5
days after delayed intra-arterial gene delivery in ischemic
hindlimb. Band visualized at 140 kd. Ad-E1, Gastrocnemius mus-
cle after delivery of Ad-E1; AdeNOS, gastrocnemius muscle after
delivery of AdeNOS; L, left gastrocnemius muscle (ischemic); 
R, right gastrocnemius muscle.
Fig 6. Immunohistochemical staining for eNOS protein in gas-
trocnemius muscle harvested 3 days after delayed intra-arterial
gene delivery in ischemic hindlimb that was transduced with 
Ad-E1 (A) and AdeNOS (B). Note that positive stain for eNOS
protein (reddish-brown staining) is demonstrated to be much
stronger in AdeNOS transduced compared with Ad-E1 trans-
duced gastrocnemius muscle(80X).
Fig 4. Effect of delayed gene delivery, cyclosporine, and psoralen
on development of gangrene after intra-arterial delivery of adeno-
virus. A, 14 days after delayed intra-arterial delivery of PBS. B, 6
days after intra-arterial delivery of Ad-E1 at 1 × 109 pfu/mL 
and treatment with cyclosporine. C, 14 days after delayed intra-
arterial delivery of Ad-E1 at 1 × 1010 pfu/mL. D, 5 days after
intra-arterial delivery of psoralen inactivated Ad-E1.
This study is the first report of adenoviral gene trans-
fer in acute limb ischemia, and our unanticipated finding
of adenoviral-induced gangrene suggests that these vec-
tors should be used with caution in acute limb ischemia.
Although adenoviral vectors are highly efficient means by
which to achieve gene transfer and hold promise for the
treatment of vascular disorders, inflammatory host
responses and brevity of transgene expression have limited
their use. Adenovirus-mediated gene transfer to large
arteries17,18 and capillaries3 results in transient expression
of biologically significant amounts of transgene products.
Exposure of normal arteries to adenovirus, however, has
deleterious effects including the development of neointi-
mal hyperplasia, lymphocyte infiltration of the vessel wall,
and endothelial cell activation.7 Furthermore, administra-
tion of adenoviral vectors to arteries of hypercholes-
terolemic rabbits1 and nonhuman primates8 accelerates
the development of macrophage-rich intimal lesions. We
have also extended these findings significantly by demon-
strating that increased inflammatory cellular infiltration
and edema with adenoviral vectors may exacerbate acute
limb ischemia, leading to gangrene and tissue loss. The
development of gangrene may be specific to intra-arterial
administration of adenoviral vectors, causing a compart-
ment syndrome, and it may be possible that intramuscular
injection of adenovirus may not induce a similar response.
Our studies suggest that the exacerbation of acute
limb ischemia by adenoviral vectors is mediated by host
immune responses targeted toward viral capsid proteins.
Although the adenoviral vector may contain other pro-
teins, the capsid proteins comprise approximately 70% of
the total adenoviral protein.11 Also, inhibition of adenovi-
ral DNA transcription by psoralen-inactivation failed to
prevent the development of gangrene. Similar reports of
inflammatory cellular infiltration of rat salivary glands19
and murine lungs20 after exposure to psoralen-inactivated
adenovirus support our findings. The use of psoralen
excludes the possibility that vector gene expression is
responsible for the inflammation seen in our study. Later
generations of adenoviral vectors have extensive deletions
in the viral genome, which decrease expression of viral
genes and have demonstrated decreased inflammation in
other in vivo models.16 Our findings with psoralen suggest
that these modified vectors will not prevent development
of gangrene because their viral packaging proteins are
identical to first-generation adenoviral vectors.
Prevention of gangrene in our model by immunosup-
pression with cyclosporine confirms that host-immune
responses contribute to the deleterious effects observed
after administration of adenoviral vectors to acutely
ischemic limbs. By itself, acute limb ischemia is character-
ized by inflammation.21 The addition of host-inflammatory
responses to adenoviral proteins in this setting undoubtedly
increases tissue injury, causing gangrene. Adenoviral vectors
with modified capsid proteins, nonviral vectors, or im-
munosuppression treatment may therefore be helpful in
preventing the adverse effects of adenoviral gene transfer to
ischemic limbs.
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Although the administration of adenoviral vectors to
acutely ischemic limbs causes gangrene, delaying vector
administration for 10 days mitigated this effect.
Importantly, we found that delay of vector administration
not only prevents gangrene but also leads to significant
transgene expression. After the administration of
AdeNOS, eNOS protein in the gastrocnemius muscle
detected with Western blotting and immunohistochem-
istry was more abundant than control (Ad-E1)–treated
limbs. Greater eNOS protein also resulted in elevated
NOS activity within ischemic rat hindlimb muscle. These
findings confirm that overexpression of specific transgenes
within capillary endothelium and skeletal muscle of
ischemic limbs is possible and holds promise for the treat-
ment of critical limb ischemia.
In summary, capillary and skeletal muscle adenoviral
gene transfer in the setting of acute limb ischemia elicits a
host-inflammatory response that leads to gangrene. This
effect was prevented by delayed administration of adeno-
viral vectors after the development of ischemia or by
immunosuppression. This dramatic and possibly clinically
significant complication of adenovirus administration in
the face of acute ischemia is particularly relevant given the
recent focus on potential adverse effects of adenoviral vec-
tors in human gene therapy trials.22 Circumventing these
barriers will allow the development of safe gene therapy
approaches for the treatment of critical limb ischemia.
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assistance in analysis and Darren Schneider, MD, for his
help and collaboration.
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